Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Pharmaceutical Business Review
Return to: PBR Home
Search Refinements

News

View news from other Pharmaceutical sectors:
136-150 of 50289 results
Astellas, Affinivax to develop MAPS vaccine targeting pneumococcal disease
Affinivax and Astellas Pharma have signed an exclusive worldwide license agreement to develop and market a vaccine targeting Streptococcus pneumoniae (pneumococcus).
Drug Research > Drug Discovery & Development > News
Kite Pharma's cancer therapy study shows good results in first CAR-T trial
By PBR Staff Writer
Kite Pharma’s axicabtagene ciloleucel demonstrated an objective response rate (ORR) of 82% and a complete response (CR) rate of 54% for patients with aggressive non-Hodgkin lymphoma in the ZUMA-1 trial.
Contract Research & Services > Clinical Trials > News
WHO reaffirms critical need for R&D for drug-resistant tuberculosis
The World Health Organization (WHO) has stressed the urgent requirement for research and development (R&D) of new antibiotics to handle the threat posed by drug-resistant tuberculosis (TB).
Drug Research > Drug Discovery & Development > News
FDA grants priority review for EMD Serono's avelumab for metastatic urothelial carcinoma
By PBR Staff Writer
The US Food and Drug Administration (FDA) has granted priority review for EMD Serono's biologics license application (BLA) of avelumab to treat metastatic urothelial carcinoma (mUC).
Production & Manufacturing > Process & Production > News
Pharma Two B raises $30m for trial of Parkinson's treatment
Pharma Two B, a privately held biopharmaceutical firm engaged in the development of treatments for Parkinson’s disease, has closed $30m financing round.
Drug Research > Drug Discovery & Development > News
Advaxis licenses antigen delivery technology to Sellas for cancer immunotherapy development
Advaxis has licensed its Lm-based antigen delivery technology to Sellas, under a cancer immunotherapy collaboration that could generate up to $358m for Advaxis.
Contract Research & Services > Contract Services > News
La Jolla’s blood pressure drug meets primary endpoint in phase 3 trial
By PBR Staff Writer
La Jolla Pharmaceutical’s catecholamine resistant hypotension (CRH) drug, LJPC-501 (angiotensin II) has met its primary endpoint in a phase 3 study.
News
Sanofi, Lonza to build EUR270m biologics production facility in Switzerland
By PBR Staff Writer
Sanofi and Lonza have agreed to invest an initial CHF290m (€270m) to construct a mammalian cell culture facility for monoclonal antibody production in Visp, Switzerland.
Production & Manufacturing > Manufacturing > News
EMA's CHMP recommends approval of Novartis’ Tafinlar in combination with Mekinist
The Committee for Medicinal Products for Human Use (CHMP) has recommended approval to the European Medicines Agency (EMA) of Novartis’ Tafinlar (dabrafenib) in combination with Mekinist (trametinib) as therapy for advanced or metastatic non-small cell lung cancer (NSCLC) patients whose tumors express the BRAF V600 mutation.
Production & Manufacturing > Process & Production > News
Oxford BioMedica’s TroVax phase I/II trial yields encouraging results
Oxford BioMedica announced that a phase I/II clinical trial of MVA-5T4 immunotherapy (TroVax) and low dose cyclophosphamide (CPM) has yielded encouraging results in patients with advanced colorectal cancer (TaCTiCC).
Contract Research & Services > Clinical Trials > News
AstraZeneca gets positive CHMP recommendation for hyperkalaemia drug
By PBR Staff Writer
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of AstraZeneca’s ZS-9 (sodium zirconium cyclosilicate) to treat hyperkalaemia.
Production & Manufacturing > Process & Production > News
Merck’s trial of inactivated varicella zoster virus vaccine meets primary end point
By PBR Staff Writer
Merck’s inactivated varicella zoster virus vaccine (VZV), V212, has met its primary endpoint in the first phase III study.
Contract Research & Services > Clinical Trials > News
Cyclacel's leukemia drug for elderly patients fails in phase 3 trial
By PBR Staff Writer
Cyclacel Pharmaceuticals’ leukemia drug for elderly patients failed to meet its primary endpoint in a phase 3 study.
Contract Research & Services > Clinical Trials > News
ProMetic’s pulmonary fibrosis drug yields positive results in phase 2 trial
ProMetic Life Sciences has revealed positive results for PBI-4050 from its open label Phase 2 clinical trial in idiopathic pulmonary fibrosis ("IPF") patients.
Contract Research & Services > Clinical Trials > News
Incyte partners with University of Pennsylvania on cancer immunotherapy research
Incyte has entered into multi-year research collaboration with the Abramson Cancer Center at the University of Pennsylvania.
Drug Research > Drug Discovery & Development > News
136-150 of 50289 results